Progestin Tx reasonably effective for early endometrial cancer

July 3, 2013
Progestin tx reasonably effective for early endometrial cancer
Conservative management with oral progestin can be a reasonable treatment option for many patients with stage 1A endometrial cancer, according to research published in the July issue of Obstetrics & Gynecology.

(HealthDay)—Conservative management with oral progestin can be a reasonable treatment option for many patients with stage 1A endometrial cancer, according to research published in the July issue of Obstetrics & Gynecology.

Jeong-Yeol Park, M.D., Ph.D., from the University of Ulsan in Korea, and colleagues reviewed the medical records of 48 women (age 40 years or younger) with endometrioid adenocarcinoma of the uterus who were treated conservatively with oral .

The researchers found that 14 (29.2 percent) received daily oral megestrol acetate (median dose, 160 mg per day) and 34 patients (70.8 percent) received daily oral medroxyprogesterone acetate (median dose, 500 mg per day). After the median treatment duration of 10 months, 37 patients (77.1 percent) had complete responses. For patients with stage IA, grade 2 to 3 without myometrial invasion (17 patients), complete response was 76.5 percent; for patients with stage IA, grade 1 with superficial myometrial invasion (23), complete response was 73.9 percent; and for patients with stage IA, grade 2 to 3 with superficial myometrial invasion (eight), complete response was 87.5 percent). After a median follow-up time of 48 months, recurrence rates for 37 patients who had achieved a complete response were 23.1, 47.1, and 71.4 percent, respectively. No disease progression or death from the disease occurred. Nine patients gave birth to 10 healthy newborns.

"Progestin treatment appears to be reasonably effective for patients with stage IA, grade 2 to 3 differentiation without myometrial invasion and patients with stage IA grade 1 differentiation with superficial myometrial invasion," the authors write.

Explore further: Chemo combination promising for multiple myeloma

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Chemo combination promising for multiple myeloma

May 2, 2012
(HealthDay) -- For patients with relapsed or refractory multiple myeloma, combination treatment with elotuzumab, lenalidomide, and low-dose dexamethasone is generally well tolerated, with encouraging response rates, according ...

Prognostic factors identified in mucoepidermoid carcinoma

August 10, 2012
(HealthDay) -- Diagnosis of low- or intermediate-grade tumors is associated with significantly better overall survival and disease-free survival in patients with mucoepidermoid carcinoma (MEC) of the salivary glands, while ...

ASCO: Dabrafenib/Trametinib active in metastatic melanoma

May 17, 2012
(HealthDay) -- For patients with V600 BRAF-mutant solid tumors, treatment with the oral BRAF inhibitor dabrafenib and the oral MEK 1/2 inhibitor trametinib is tolerated and has clinical activity in BRAF inhibitor-naive metastatic ...

Ibrutinib continues strong showing against mantle cell lymphoma

June 19, 2013
In a major international study led by researchers at The University of Texas MD Anderson Cancer Center, the targeted therapy ibrutinib continues to show remarkable promise for the treatment of relapsed or refractory mantle ...

Low-risk bladder cancer rarely progresses to muscle invasion

March 6, 2013
(HealthDay)—Low-risk bladder cancer rarely progresses to muscle invasion but is associated with an increased risk of disease-specific mortality compared with matched populations, according to research published in the March ...

Recommended for you

Population health impact of infants born small for gestational age in low- and middle-income countries

August 18, 2017
In low-and middle-income countries, it is common for babies to be born of low birth weight, due to either inadequate growth in utero (fetal growth restriction) and/or preterm birth, (birth before 37 weeks gestation). Maternal ...

Hormone from fat tissue can give protection against polycystic ovary syndrome

August 10, 2017
Obesity and reduced insulin sensitivity are common in polycystic ovary syndrome, PCOS. New research based on animal studies, and to be published in the journal PNAS, reveals that the hormone adiponectin can protect against ...

Study in mice may reveal insights into causes of miscarriages for some women

August 9, 2017
Researchers at St. Michael's Hospital have identified how natural killer cells in the mouse placenta can cause a fetus to fail to grow in the womb or cause miscarriages.

Insomnia, sleep apnea nearly double the risk of preterm delivery before 34 weeks

August 9, 2017
Pregnant women who are diagnosed with sleep disorders such as sleep apnea and insomnia appear to be at risk of delivering their babies before reaching full term, according to an analysis of California births by researchers ...

Elective freezing of IVF embryos linked to higher pregnancy rates in some cases

August 1, 2017
A delay in transferring embryos to the mother improves the success of in vitro fertilization in certain cases, according to a study by scientists at the Stanford University School of Medicine, Celmatix Inc. and several other ...

Negative birth outcomes linked to air pollution exposure early in pregnancy, study finds

July 27, 2017
Exposure to air pollution early in a pregnancy could increase risk for preterm birth and low birth weight, according to a study led by researchers at NYU School of Medicine, and published on July 27 in Environmental Health ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.